StockCIK 1601830

RECURSION PHARMACEUTICALS, INC. (RXRX): Insider Trades and Fund Holdings

In the past 12 months, RECURSION PHARMACEUTICALS, INC. insiders reported 0 open-market purchases worth $0 and 4 sales worth $546K; 4 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$546KSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 7, 2026.

Recent RXRX insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 7	Oct 6	Blake BorgesonDirector	Director	▼ SELL10b5-1	50,000	4.84	$242K	−0.8%	Form 4 ↗
Oct 7	Oct 6	Robert HershbergDirector	Director	▼ SELL10b5-1	25,000	5.00	$125K	−13%	Form 4 ↗
Sep 10	Sep 8	Najat KhanCEO	CEO	▼ SELL10b5-1	22,408	3.52	$79K	−1.1%	Form 4 ↗
Sep 2	Sep 1	Blake BorgesonDirector	Director	▼ SELL10b5-1	30,000	3.34	$100K	−0.5%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Bought	Sells	Sold	Latest
Blake Borgeson	Director	$0	2	$342K	Oct 7, 2026
Robert Hershberg	Director	$0	1	$125K	Oct 7, 2026
Najat Khan	CEO	$0	1	$79K	Sep 10, 2026

Tracked funds that report RXRX

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Bridgewater Associates	Q2 2026	37,667	$138K	0.00%	▲ New
Renaissance Technologies	Q2 2026	0	$0	0.00%	▼ Sold out

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →